ESCITALOPRAM Drug Patent Profile

When do Escitalopram patents expire, and when can generic versions of Escitalopram launch?

Escitalopram is a drug marketed by Almatica, Rising, Amneal Pharms, Antrim Pharms Llc, Aurobindo Pharma Ltd, Chartwell Molecular, Hetero Labs Ltd Iii, Macleods Pharms Ltd, Sun Pharma Canada, Accord Hlthcare, Aiping Pharm Inc, Ascent Pharms Inc, Chartwell Rx, Graviti Pharms, Hikma Pharms, Invagen Pharms, Jubilant Cadista, Novitium Pharma, Prinston Inc, Teva Pharms Usa, Torrent Pharms Ltd, and Zydus Lifesciences. and is included in twenty-five NDAs.

The generic ingredient in ESCITALOPRAM is escitalopram oxalate. There are twenty-six drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the escitalopram oxalate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Escitalopram

A generic version of ESCITALOPRAM was approved as escitalopram oxalate by AMNEAL PHARMS on March 14^th, 2012.

Summary for ESCITALOPRAM

US Patents:	0
Applicants:	22
NDAs:	25
Finished Product Suppliers / Packagers:	1
Clinical Trials:	430
Patent Applications:	7,051
Drug Prices:	Drug price information for ESCITALOPRAM
Drug Sales Revenues:	Drug sales revenues for ESCITALOPRAM
What excipients (inactive ingredients) are in ESCITALOPRAM?	ESCITALOPRAM excipients list
DailyMed Link:	ESCITALOPRAM at DailyMed

See drug prices for ESCITALOPRAM

See drug sales revenues for ESCITALOPRAM

Recent Clinical Trials for ESCITALOPRAM

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Moon (Guangzhou) Biotechnology Co., Ltd.	NA
National Institute of Allergy and Infectious Diseases (NIAID)	PHASE2
Cipla Ltd.	PHASE2

See all ESCITALOPRAM clinical trials

Pharmacology for ESCITALOPRAM

Drug Class	Serotonin Reuptake Inhibitor
Mechanism of Action	Serotonin Uptake Inhibitors

US Patents and Regulatory Information for ESCITALOPRAM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Jubilant Cadista	ESCITALOPRAM OXALATE	escitalopram oxalate	TABLET;ORAL	202280-003	Sep 12, 2012	AB	RX	No	No
Graviti Pharms	ESCITALOPRAM OXALATE	escitalopram oxalate	TABLET;ORAL	078777-003	Sep 11, 2012	AB	RX	No	No
Prinston Inc	ESCITALOPRAM OXALATE	escitalopram oxalate	TABLET;ORAL	078032-002	Aug 28, 2015	AB	RX	No	No
Novitium Pharma	ESCITALOPRAM OXALATE	escitalopram oxalate	TABLET;ORAL	077550-001	May 14, 2015		DISCN	No	No
Prinston Inc	ESCITALOPRAM OXALATE	escitalopram oxalate	TABLET;ORAL	078032-003	Aug 28, 2015	AB	RX	No	No

Market Dynamics and Financial Trajectory for Escitalopram

Last updated: April 4, 2026

What Is Escitalopram and Its Therapeutic Profile?

Escitalopram is a selective serotonin reuptake inhibitor (SSRI) approved for treating major depressive disorder (MDD), generalized anxiety disorder (GAD), and obsessive-compulsive disorder (OCD). It is marketed under brand names such as Lexapro and Cipralex, among others. Approved by the FDA in 2002, it is a chiral molecule, with the S-enantiomer exhibiting antidepressant activity.

Current Market Size and Growth

Global Market Value

The global pharmaceutical market for antidepressants, including escitalopram, was valued at approximately USD 20 billion in 2022. Escitalopram commands a significant share due to its efficacy and favorable side effect profile.

Segment Breakdown

Segment	Percentage of Market (2022)	Key Suppliers
SSRI antidepressants	65%	Pfizer, Lundbeck
Escitalopram's share	25% of SSRI market	Pfizer (Lexapro), Cipralex
Generic competition	Rising, 50% of sales	Multiple manufacturers

Growth Rate

The compound annual growth rate (CAGR) for the antidepressants market, driven by escitalopram, stood at 3-4% from 2018 to 2022. The growth is driven by increased prevalence of depression and anxiety, especially post-pandemic, and the expansion into emerging markets.

Patent Landscape and Market Dynamics

Patent Expiration Timeline

Pfizer's patent for Lexapro expired in the U.S. in 2012, with subsequent US patent protections ending in 2018. The off-patent status has spurred generic competition, leading to price reductions:

• Original patent: 2002–2012
• Patent expiry leading to generics: 2012–present

Impact of Patent Expiry

Generic versions account for approximately 80-90% of sales volume but at significantly lower prices, reducing brand revenue:

• Original product price: USD 10-15 per prescription
• Generics price: USD 4-7 per prescription

Emerging Markets

In countries like India and Brazil, regulatory approval of generics and biosimilars has accelerated, contributing to increased volume but lower margins.

Competitive Landscape

Major players include:

Company	Product	Market Share (2022)	Key Strategies
Pfizer	Lexapro (original brand)	45%	Focus on branded differentiation
Teva, Mylan, Sandoz	Various generics	40%	Price competition
Other manufacturers	Local generics	15%	Market penetration in emerging markets

Market share is heavily influenced by patent status, with branded sales declining while generics dominate volume.

Pricing and Reimbursement Trends

Price Trends

• Post-patent expiration, average prices plunge 50-70%
• Brand-name product: USD 10-15 per prescription
• Generics: USD 4-7 per prescription

Reimbursement Policies

• Gaining coverage in major health systems (e.g., U.S., Europe)
• Cost-containment efforts encourage generic use
• Price negotiations and formulary preferences impact revenue

Regulatory and Market Access Challenges

• Strict regulatory environments in developed markets
• Price controls in some regions (e.g., parts of Europe, Latin America)
• Biosimilar competition in later phases

Financial Trajectory

Revenue Projections (2023–2027)

Year	Estimated Revenue (USD billions)	Key Drivers
2023	USD 2.4 billion	Continued generic penetration, emerging markets growth
2024	USD 2.2 billion	Market saturation, price pressure
2025	USD 2.0 billion	Transition to biosimilars, patent challenges
2026	USD 1.8 billion	Biosimilar competition, market consolidation
2027	USD 1.7 billion	Market maturity, pricing pressures

Profitability Trends

Gross margins decreased from around 65% pre-patent expiry to 35-45% today, reflecting lower average selling prices and increased generic competition. R&D investments shift toward new antidepressant classes and combination therapies.

Future Outlook and Innovation

• Pipeline drugs focus on multimodal approaches, including serotonin-norepinephrine reuptake inhibitors (SNRIs) and novel mechanisms.
• Biosimilars and personalized medicine approaches aim to reduce costs and improve outcomes.
• Regulatory pathways for new formulations or combinations could influence future market share.

Key Takeaways

• Patents for escitalopram expired in 2012-2018, shifting revenue toward generics.
• The global antidepressant market remains steady with a CAGR of 3-4%, but margins face pressure.
• Emerging markets drive volume growth; developed markets focus on cost management.
• Competition from biosimilars and new molecules will influence long-term profitability.
• Companies investing in pipeline diversification and innovative delivery systems could mitigate revenue declines.

FAQs

1. How has patent expiration affected escitalopram sales?
Patent expiration led to a steep decline in brand-name sales and increased generic market share, with prices dropping approximately 50-70%.

2. What is the primary driver of growth in the escitalopram market?
Rising prevalence of depression and anxiety, especially in emerging markets, expanding treatment access.

3. How does pricing vary between branded and generic escitalopram?
Brand-name prescriptions cost USD 10-15; generics cost USD 4-7, with volume compensating for lower margins.

4. What competition does escitalopram face from biosimilars?
While biosimilars are more common in biologic drugs, market entry of newer antidepressants could pressure escitalopram's market share.

5. What are future innovation directions for antidepressants like escitalopram?
Focus on combination therapies, personalized medicine, and innovative delivery systems to improve efficacy and reduce side effects.

---

References

[1] MarketWatch. (2023). Antidepressants Market Size, Share & Trends Analysis.
[2] EvaluatePharma. (2022). Global Prescription Medication Revenue Data.
[3] U.S. Food and Drug Administration. (2018). Lexapro (Escitalopram) Approval and Patent Status.
[4] IMS Health. (2022). Global Pharmaceutical Market Reports.
[5] WHO. (2022). Depression and Anxiety Disorder Statistics.

DrugChatter Q&A for ESCITALOPRAM

How much weight did you gain lose on escitalopram?
How has escitalopram influenced your appetite?
Did you notice any weight change after increasing escitalopram dosage?
Conversely did escitalopram cause weight loss for you?
Conversely did escitalopram cause weight loss for you?